S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Lithium Overdose: Can These 2 Lithium Stocks Recover in 2024?
'Civil War’ continues box-office campaign at No. 1
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Intuitive Surgical Leads the Robotic Surgery Movement
Stock market today: World shares shrug off Wall St blues as investors eye corporate earnings
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Lithium Overdose: Can These 2 Lithium Stocks Recover in 2024?
'Civil War’ continues box-office campaign at No. 1
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Intuitive Surgical Leads the Robotic Surgery Movement
Stock market today: World shares shrug off Wall St blues as investors eye corporate earnings
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Lithium Overdose: Can These 2 Lithium Stocks Recover in 2024?
'Civil War’ continues box-office campaign at No. 1
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Intuitive Surgical Leads the Robotic Surgery Movement
Stock market today: World shares shrug off Wall St blues as investors eye corporate earnings
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Lithium Overdose: Can These 2 Lithium Stocks Recover in 2024?
'Civil War’ continues box-office campaign at No. 1
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Intuitive Surgical Leads the Robotic Surgery Movement
Stock market today: World shares shrug off Wall St blues as investors eye corporate earnings
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro

Acumen Pharmaceuticals (ABOS) News Today

$3.15
-0.01 (-0.32%)
(As of 04/19/2024 08:50 PM ET)
SourceHeadline
markets.businessinsider.com logoThese 2 ‘Strong Buy’ Penny Stocks Are Poised for Over 300% Gains, Say Analysts
markets.businessinsider.com - April 18 at 7:21 PM
msn.com logoAcumen Pharmaceuticals (ABOS) Price Target Increased by 6.67% to 13.06
msn.com - April 17 at 2:50 PM
globenewswire.com logoAcumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
globenewswire.com - April 16 at 8:00 AM
MarketBeat logoAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Up 21.6% in March
americanbankingnews.com - April 13 at 1:54 AM
finance.yahoo.com logoAcumen Pharmaceuticals Collaborates with Lonza For Alzheimer’s Treatment
finance.yahoo.com - April 4 at 7:02 PM
markets.businessinsider.com logoAcumen Pharma Partners Lonza To Advance Sabirnetug For Alzheimer's Disease Treatment
markets.businessinsider.com - April 4 at 9:02 AM
finance.yahoo.com logoAcumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease
finance.yahoo.com - April 4 at 9:02 AM
globenewswire.com logoAcumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer's Disease
globenewswire.com - April 4 at 8:00 AM
msn.com logoSames Auto Group partners with Driscoll Children’s Hospital
msn.com - April 4 at 4:01 AM
marketbeat.com logoAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) to Post Q2 2024 Earnings of ($0.26) Per Share, HC Wainwright Forecasts
marketbeat.com - March 29 at 8:36 AM
marketbeat.com logoAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Forecasted to Post Q1 2024 Earnings of ($0.26) Per Share
marketbeat.com - March 28 at 8:24 AM
msn.com logoAcumen Pharmaceuticals files for $200M mixed shelf offering
msn.com - March 27 at 9:00 PM
markets.businessinsider.com logoBuy Rating Affirmed for Acumen Pharmaceuticals on Promising Alzheimer’s Drug Trial Outcomes
markets.businessinsider.com - March 27 at 3:59 PM
markets.businessinsider.com logoBuy Rating Affirmed for Acumen Pharmaceuticals Amid Promising Alzheimer’s Treatment Development and Attractive Valuation
markets.businessinsider.com - March 27 at 3:59 PM
finance.yahoo.com logoQ4 2023 Acumen Pharmaceuticals Inc Earnings Call
finance.yahoo.com - March 27 at 10:58 AM
finance.yahoo.com logoAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q4 2023 Earnings Call Transcript
finance.yahoo.com - March 27 at 10:58 AM
marketbeat.com logoAcumen Pharmaceuticals (NASDAQ:ABOS) Stock Rating Reaffirmed by HC Wainwright
marketbeat.com - March 27 at 10:15 AM
globenewswire.com logoAcumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights
globenewswire.com - March 26 at 7:00 AM
marketbeat.com logoAcumen Pharmaceuticals (ABOS) Scheduled to Post Quarterly Earnings on Tuesday
marketbeat.com - March 20 at 3:04 PM
globenewswire.com logoAcumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024
globenewswire.com - March 19 at 4:00 PM
globenewswire.com logoAcumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days
globenewswire.com - March 12 at 4:00 PM
finance.yahoo.com logoAcumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
finance.yahoo.com - March 8 at 11:04 AM
marketbeat.com logoSchonfeld Strategic Advisors LLC Takes $2.68 Million Position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS)
marketbeat.com - March 7 at 6:40 AM
finance.yahoo.com logoInstitutional investors own a significant stake of 42% in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS)
finance.yahoo.com - February 24 at 9:24 AM
finance.yahoo.com logoAcumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
finance.yahoo.com - February 21 at 12:31 PM
globenewswire.com logoAcumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer's at the AD/PD™ 2024 Annual Meeting
globenewswire.com - February 21 at 8:00 AM
finance.yahoo.com logoABOS Mar 2024 2.500 put
finance.yahoo.com - February 17 at 1:28 AM
finance.yahoo.com logoBuy Alert: 3 Healthcare Stocks Sitting in the Sweet Spot
finance.yahoo.com - February 7 at 3:51 AM
finance.yahoo.com logo3 Healthcare Stocks to Buy as the Sector Benefits from the Aging Boom
finance.yahoo.com - February 1 at 8:58 AM
finance.yahoo.com logoAcumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer
finance.yahoo.com - February 1 at 8:58 AM
marketbeat.com logoAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) COO Sells $10,567.09 in Stock
marketbeat.com - January 19 at 9:19 PM
markets.businessinsider.com logoBTIG Reaffirms Their Buy Rating on Acumen Pharmaceuticals (ABOS)
markets.businessinsider.com - January 8 at 8:38 AM
finance.yahoo.com logoAcumen Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 4 at 6:15 PM
msn.com logoDeutsche Bank Initiates Coverage of Acumen Pharmaceuticals (ABOS) with Buy Recommendation
msn.com - December 13 at 7:37 AM
finance.yahoo.com logoAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q3 2023 Earnings Call Transcript
finance.yahoo.com - November 14 at 1:23 PM
finance.yahoo.com logoQ3 2023 Acumen Pharmaceuticals Inc Earnings Call
finance.yahoo.com - November 14 at 1:18 AM
finance.yahoo.com logoAcumen Pharmaceuticals Inc (ABOS) Reports Q3 2023 Financial Results and Provides Business Update
finance.yahoo.com - November 13 at 3:17 PM
markets.businessinsider.com logoAcumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights
markets.businessinsider.com - November 13 at 10:16 AM
markets.businessinsider.com logoAcumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures
markets.businessinsider.com - November 13 at 10:16 AM
benzinga.com logoAcumen Pharmaceuticals's Earnings Outlook
benzinga.com - November 10 at 6:01 PM
msn.com logoHalozyme, Acumen enter collaboration for Alzheimer's drug candidate
msn.com - November 7 at 1:00 PM
finance.yahoo.com logoQ3 2023 Halozyme Therapeutics Inc Earnings Call
finance.yahoo.com - November 7 at 1:00 PM
finance.yahoo.com logoAcumen Pharmaceuticals to Report Third Quarter Financial Results on November 13, 2023
finance.yahoo.com - November 6 at 8:38 PM
finance.yahoo.com logoAcumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of ACU193 with ENHANZE® Technology
finance.yahoo.com - November 6 at 10:37 AM
finance.yahoo.com logoAcumen Pharmaceuticals to Participate in the UBS Biopharma Conference
finance.yahoo.com - November 2 at 5:30 PM
msn.com logoAcumen’ presents new data on its ACU193 in Phase I trial for AD
msn.com - October 31 at 1:08 AM
markets.businessinsider.com logoAnalysts Offer Insights on Healthcare Companies: Acumen Pharmaceuticals (ABOS) and Alector (ALEC)
markets.businessinsider.com - October 30 at 10:06 AM
finance.yahoo.com logoAcumen Pharmaceuticals Presents Late-Breaker Phase 1 Updates Exploring Novel Target Engagement, Dosing Regimen and Safety Findings for ACU193 in Early Alzheimer’s Disease at the 16th Annual Clinical Trials on Alzheimer’s Disease
finance.yahoo.com - October 27 at 1:14 PM
finance.yahoo.com logoAcumen Pharmaceuticals to Present Deeper Insights from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s During Symposium at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD)
finance.yahoo.com - October 4 at 8:08 AM
msn.com logoNavigating Acumen's Alzheimer's Risk And Reward
msn.com - October 3 at 2:48 PM
Get Acumen Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ABOS and its competitors with MarketBeat's FREE daily newsletter.

Now Open: Crypto emergency update (Ad)

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

ABOS Media Mentions By Week

ABOS Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ABOS
News Sentiment

0.53

0.48

Average
Medical
News Sentiment

ABOS News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ABOS Articles
This Week

3

2

ABOS Articles
Average Week

Get Acumen Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ABOS and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:ABOS) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners